Charles River Laboratories Intl. Inc vs Financial Select Sector SPDR Fund — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Financial Select Sector SPDR Fund trades at $56.63. Which is the better fit depends on your goals.
| CRL | XLF | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | — |
52-Week High | $233.60 | $56.56 |
52-Week Low | $145.57 | $47.80 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
XLF trades at $56.07, up 0.65% with a bullish technical outlook supported by moving averages. The ETF benefits from strong bank earnings expectations and potential Federal Reserve rate hikes. Recent news highlights sector resilience amid geopolitical tensions and AI-driven market shifts.
Outlook remains positive with earnings season as a catalyst, though risks include economic slowdowns and regulatory pressures. Analyst sentiment leans bullish with institutional focus on dividend growth and financial stability.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →